Reporter brief
A Randomized Placebo-controlled Trial of Nicotinamide/Pterostilbene Supplement in ALS: The NO-ALS Study
What happened
Trial registry update: ACTIVE_NOT_RECRUITING. No results reported in the supplied registry record.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- No efficacy data are reported in this abstract, so the safety or effectiveness of this combination cannot be assessed from this source.
- The theoretical rationale linking NAD/sirtuin pathways to ALS progression does not confirm that this specific intervention would work in patients.
- The study's design and recruitment plan tell us nothing about whether results were positive, negative, or neutral.
Study design and sample
Rct; Human.
Patients with Amyotrophic Lateral Sclerosis (ALS). Average survival from diagnosis is 3 years.
- Design
- Rct
- Sample
- 180
- Journal
- Haukeland University Hospital
- Published
- Oct 5, 2026
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Nicotinamide riboside timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.